Skip to main content

Drug Interactions between darunavir and nevirapine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

nevirapine darunavir

Applies to: nevirapine and darunavir

GENERALLY AVOID: Coadministration of darunavir-cobicistat with nevirapine may decrease the plasma concentrations of darunavir and/or cobicistat and increase the plasma concentrations of nevirapine. Reduced darunavir plasma levels may lead to diminished virologic response and possible resistance to darunavir. Increased nevirapine plasma concentrations may increase the risk of nevirapine-associated toxicity, including hepatotoxicity, fatal and non-fatal skin reactions (e.g., Stevens Johnson syndrome), and hypersensitivity reactions. The mechanism is nevirapine induction of the CYP450 3A4 isoenzyme and inhibition of CYP450 3A4 activity by darunavir and cobicistat. Pharmacokinetic data are not available for darunavir-cobicistat. However, when darunavir 400 mg-ritonavir 100 mg twice daily was used concomitantly with nevirapine 200 mg twice daily, there was increased systemic exposure (AUC) to nevirapine and darunavir of 27% and 24%, respectively. However, the trough plasma concentration (Cmin) of darunavir was unaffected. These changes are not considered to be clinically significant and do not warrant a dose adjustment to the standard recommended dose of darunavir-ritonavir.

MANAGEMENT: The concomitant use of darunavir-cobicistat with nevirapine is not recommended. As an alternative, darunavir boosted by low-dose ritonavir may be considered for use in combination with nevirapine.

References

  1. (2001) "Product Information. Viramune (nevirapine)." Boehringer-Ingelheim
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  3. (2006) "Product Information. Prezista (darunavir)." Ortho Biotech Inc
  4. Cerner Multum, Inc. "Australian Product Information."
  5. (2014) "Product Information. Prezcobix (cobicistat-darunavir)." Janssen Pharmaceuticals
View all 5 references

Switch to consumer interaction data

Drug and food interactions

Moderate

darunavir food

Applies to: darunavir

ADJUST DOSING INTERVAL: Food enhances the absorption and oral bioavailability of darunavir administered in combination with low-dose ritonavir. The mechanism is unknown. When administered with food, the peak plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) of darunavir were approximately 30% higher than when administered in the fasting state. Darunavir exposure was similar for the range of meals studied. The total caloric content of the various meals evaluated ranged from 240 Kcal (12 grams fat) to 928 Kcal (56 grams fat).

MANAGEMENT: To ensure maximal oral absorption, darunavir coadministered with ritonavir should be taken with food. The type of food is not important.

References

  1. (2006) "Product Information. Prezista (darunavir)." Ortho Biotech Inc

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer